Christine Ring - 30 Jul 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: Chief Legal Officer
Issuer ticker: NRIX
Reported as of: 30 Jul 2026
Net transaction value: -$89,954
SEC form: 4
Accepted by SEC: 30 Jul 2026, 17:56:08 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring

Key filing fact

Christine Ring filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 30 Jul 2026.

Key facts

This page summarizes Christine Ring's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
7 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 30 Jul 2026, 17:56.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: -$89,954.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001817199 Primary reporting owner

Ring Christine

Relationship: Chief Legal Officer
Address: C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE
Signature: /s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring
Signature date: 30 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRIX transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,750
Change %: +28%
Price: $0.000000^*
Shares after: 17,329
Date: 30 Jul 2026
Ownership: Direct

NRIX transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,858
Change %: +16%
Price: $0.000000^*
Shares after: 20,187
Date: 30 Jul 2026
Ownership: Direct

NRIX transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,572
Change %: +18%
Price: $0.000000^*
Shares after: 23,759
Date: 30 Jul 2026
Ownership: Direct

NRIX transaction

Common Stock

Sale

Transaction value: $89,954
Shares: -3,847
Change %: -16%
Price: $23.38
Shares after: 19,912
Date: 30 Jul 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -3,750
Change %: -25%
Price: $0.000000^*
Shares after: 11,250
Date: 30 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,750
Exercise price: $0.000000
Footnotes: F3, F4, F5

NRIX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -2,858
Change %: -12%
Price: $0.000000^*
Shares after: 20,009
Date: 30 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,858
Exercise price: $0.000000
Footnotes: F3, F5, F6

NRIX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -3,572
Change %: -8.3%
Price: $0.000000^*
Shares after: 39,303
Date: 30 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,572
Exercise price: $0.000000
Footnotes: F3, F5, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Footnote F2

Represents the weighted average sale price. The lowest price at which shares were sold was $23.00 and the highest price at which shares were sold was $23.90. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Footnote F3

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F4

The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

Footnote F5

RSUs do not expire; they either vest or are canceled prior to the vest date.

Footnote F6

The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

Footnote F7

The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.